Image via Wikipedia
BioTime Inc.announced today that it has initiated shipments of stem cell research products to its worldwide distributor, Millipore Corporation, according to the terms of the co-marketing agreement between the two companies that was announced on July 9, 2009. BioTime has shipped inventory of six ACTCellerate™ progenitor cell lines to Millipore and plans to begin shipments of additional cell lines and ESpan™ cell growth media in the next several weeks. Derived from human embryonic stem cells but not fully differentiated into specific cell types, each ACTCellerate™ line provides a convenient, highly purified source of progenitor cells that may
British scientists have reportedly perfected the technique for curing macular-degeneration related blindness with adult stem cells. Returning Hope, a pioneering Asian adult stem cell treatment portal, expects to be one of the first in the world to offer the treatment.
Researchers from the Institute of Ophthalmology at London’s University College used embryonic eye stem cells to replace the layer of damaged eye cells. While Pfizer is backing the British push to bring the therapy to patients, Brian Dardzinski, CEO of Returning Hope, expects that Adult Stem Cell treatments will be available both much sooner and much cheaper in Thailand.
Another project is added to the controversial law that could be adopted this year to regulate all matters relating to the conservation and use of stem cells. MPP deputy Alvaro Vega drives its nationalization.
The Frente Amplio (FA) reopened the file a bill that allows the conservation and use of newborn stem cells to cure genetic diseases.
Rep. Alvaro Vega (MPP) told El Pais that the initiative is a priority in the Health Commission, so that from the FA will promote parliamentary approval this year.
The bill for the “collection and use of human tissues and cells” must be based on that
Image via Wikipedia
CINCINNATI—New research from the University of Cincinnati may help in the recovery of lost vision for patients with corneal scarring.
Winston Whei-Yang Kao, PhD, professor of ophthalmology, along with other researchers in UC’s ophthalmology department found that transplanting human umbilical mesenchymal stem cells into mouse models that lack the protein lumican restored the transparency of cloudy and thin corneas.
Mesenchymal stem cells are “multi-potent” stem cells that can differentiate into a variety of cell types.
These findings are being presented Dec. 8 in San Diego at the 49th Annual Meeting of the American Society of Cell Biology.
“Corneal transplantation is currently